Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics has announced that the first patient has been dosed in the Phase 3 pivotal cohort of the LIGHTHOUSE trial evaluating ATSN-201 for the treatment of X-linked retinoschisis.
Inzecto Announces Newly Granted Upgraded EPA Registration Providing Three Months of Continuous Mosquito Control (USA Today)
UF startup INZECTO announces a newly upgraded EPA registration for its innovative Mosquito Trap, providing three months of continuous control.
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers (PR Newswire)
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of molecularly defined subsets of AML and other blood related cancers.
Neuropacs Announces the Publication of a New Study Comparing the First-of-Its-Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease With CSF Alpha-Synuclein Seed Amplification Assay (Business wire)
UF startup Neuropacs announced new research highlighting its AI-powered Parkinson’s diagnostic technology, which recently received FDA clearance for clinical use.
Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial (PR Newswire)
UF startup Rise Therapeutics has completed enrollment in a Phase 1b clinical trial evaluating its oral immunotherapy candidate for patients with active rheumatoid arthritis.
Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-Muscle Myosin II in Newly Diagnosed Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics has dosed the first patient in its Phase 1/2 glioblastoma trial, advancing the development of a potential new cancer therapy in collaboration with the Mayo Clinic and NCI.
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy (Globe Newswire)
Solid Biosciences, which acquired UF startup AavantiBio, announced that the first patient has been dosed in its Phase 3 trial of SGT-003 for Duchenne muscular dystrophy.
Atsena Presents Positive Interim Six-Month Results From Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients With X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics reported encouraging six-month clinical trial results showing improved vision and a favorable safety profile for its gene therapy targeting X-linked retinoschisis.
Kriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy Platform (Globe Newswire)
UF startup Kriya Therapeutics will present multiple gene therapy advances at the 2026 ASGCT Annual Meeting, highlighting its efforts to make treatments for chronic diseases more accessible.
FDA Approves First Gene Therapy for Inherited Deafness, Shown To Restore Hearing for Children With Rare Condition (CNN)
Regeneron, which licenses technology developed by UF researcher Sanford Boye and team, is advancing gene therapy research that could restore hearing in people with inherited deafness.